Pfizer Zyrtec-D Indicated For Allergic Rhinitis In Patients 12 And Older
This article was originally published in Pharmaceutical Approvals Monthly
Pfizer’s antihistamine/decongestant combination tablet Zyrtec-D 12 Hour (cetirizine 5 mg/pseudoephedrine 120 mg) cleared FDA Aug. 10 "for relief of nasal and non-nasal symptoms associated with seasonal or perennial allergic rhinitis in adults and children 12 years of age and older."
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class